Skip to content

Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis POSEIDON Group 4 Patients: A Single-Center, Parallel-Group, Open-Label Randomized Controlled Trial

Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis POSEIDON Group 4 Patients: A Single-Center, Parallel-Group, Open-Label Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600123535
Enrollment
Unknown
Registered
2026-04-27
Start date
2026-05-04
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility

Interventions

D2 Embryo Transfer Group:Fresh embryo transfer on day 2 after oocyte retrieval
D3 Embryo Transfer Group:Fresh embryo transfer on day 3 after oocyte retrieval

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1.Meet the definition of POSEIDON Category 4: age = 35 years, with antral follicle count (AFC) < 5 or anti-Müllerian hormone (AMH) < 1.2 ng/mL; 2.Undergoing first or second IVF/ICSI cycle; 3.Undergoing controlled ovarian hyperstimulation (COH) using a gonadotropin-releasing hormone (GnRH) antagonist protocol, with at least 1 oocyte retrieved; 4.Provide written informed consent;

Exclusion criteria

Exclusion criteria: 1. Use of donor oocytes/sperm, or planned preimplantation genetic testing (PGT); 2. Severe immune or chromosomal abnormalities; 3. Uterine cavity abnormalities (i.e., submucous fibroids, complete uterine septum, severe intrauterine adhesions, etc.) or untreated, ultrasound-visible hydrosalpinx; 4. Presence of severe underlying diseases (e.g., uncontrolled hypertension/diabetes mellitus, active malignant tumors); 5. History of recurrent implantation failure (>=2 cycles) or recurrent miscarriage (>=2 episodes); 6. Progesterone level > 1.5 ng/mL on the day of human chorionic gonadotropin (hCG) trigger;

Design outcomes

Primary

MeasureTime frame
Live birth rate;

Secondary

MeasureTime frame
Congenital malformation rate;Low birth weight rate;Embryo utilization rate;Moderate/severe OHSS incidence rate;Miscarriage rate;Clinical pregnancy rate;Implantation rate;Rate of no available embryos;Biochemical pregnancy rate;Preterm birth rate;Ongoing pregnancy rate;

Countries

China

Contacts

Public ContactJiang Shutian

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

shutiansweet@126.com+86 21 2327 1699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026